The ReProgram

🎬 EPISODE OVERVIEWDoes resveratrol live up to the longevity hype? We examine the clinical data to see if it actually improves health markers.Research into this supplement often focuses on molecular changes, but we look at how resveratrol impacts real-world patient outcomes. By analyzing studies on cardiovascular health, inflammation, and cognitive function, we distinguish between theoretical benefits and proven clinical results. This scorecard provides a clear framework for evaluating whether the current evidence justifies its use as a longevity intervention.We also compare how different patient groups respond to this compound, highlighting where the data remains inconclusive. Understanding these limitations is essential for anyone trying to separate marketing claims from rigorous science. This analysis is for those who prioritize evidence-based health decisions over popular trends.If you value longevity science without the hype, subscribe to The ReProgram.🔑 KEYWORDSResveratrol • Longevity • Human Trials • Healthy Aging • Evidence Scorecard • Supplements📌 KEY TAKEAWAYS• Changes in selected markers do not establish longer human life.• Study population, dose and outcome shape what a finding means.• Better cognitive test scores do not demonstrate dementia prevention.• Natural origin does not settle safety or medication interactions.• Ask what was measured, in whom, and whether the benefit matters.🎙️ THE REPROGRAM PERSPECTIVEA molecule can be biologically interesting while its value as an everyday supplement remains uncertain. We should be able to hold both ideas at once. The score can change when the evidence changes.⏱️ CHAPTERS00:00 Resveratrol and its claims01:09 How the scorecard works02:04 Biology and the early animal studies03:38 Absorption and exposure04:08 Metabolic markers05:52 Cardiovascular claims06:36 The exercise trial07:39 Cognition and dementia distinctions09:40 Inflammatory markers11:08 Human lifespan12:01 Safety and drug interactions13:36 The final scorecard and C− grade14:40 What better evidence would look like14:56 Three questions for any longevity claim📝 NOTES AND REFERENCESBaur et al. (2006), high-calorie-diet mice:https://doi.org/10.1038/nature05354Miller et al. (2011), mouse lifespan:https://doi.org/10.1093/gerona/glq178Timmers et al. (2011), metabolic study:https://doi.org/10.1016/j.cmet.2011.10.002Yoshino et al. (2012), nonobese women:https://doi.org/10.1016/j.cmet.2012.09.015Sun et al. (2026), umbrella review:https://doi.org/10.1186/s12937-026-01319-5Gliemann et al. (2013), exercise trial:https://pubmed.ncbi.nlm.nih.gov/23878368/Thaung Zaw et al. (2021), cognition crossover trial:https://doi.org/10.1016/j.clnu.2020.08.025Wightman et al. (2026), cognition review:https://doi.org/10.3389/fnut.2026.1839709RESET / JOTROL trial: investigational formulation, not an efficacy result:https://clinicaltrials.gov/study/NCT07592767Zhu et al. (2025), inflammatory markers:https://doi.org/10.3389/fendo.2024.1463027Brown et al. (2010), repeated-dose safety:https://doi.org/10.1158/0008-5472.CAN-10-2364Chow et al. (2010), drug-metabolizing enzymes:https://doi.org/10.1158/1940-6207.CAPR-09-0155💬 JOIN THE CONVERSATIONWhich result would most change your view of resveratrol: better function, fewer clinical events, or longer life? Tell us why.Subscribe for longevity biology without the hype:https://www.youtube.com/@ReProgramPodcastMechanism over marketing. Evidence over anecdotes. Trade-offs over hype.

🎬 EPISODE OVERVIEWCan we reverse aging? We examine what recent clinical announcements actually prove about the state of human longevity science.Recent reports regarding partial cellular reprogramming have sparked debate about the potential for human age reversal. We break down the distinction between clinical benefit and actual tissue rejuvenation, focusing on what early findings from human trials really indicate. By separating marketing claims from biological reality, we clarify how these interventions affect cellular function.Understanding the limits of current research is vital for anyone interested in healthy aging. We analyze why improvements in specific metrics, such as visual-field tests, do not necessarily equate to a universal reset of the aging process. This assessment provides a grounded look at how we measure progress in the field of longevity and what future experiments must demonstrate to validate these early observations.If you value longevity science without the hype, subscribe to The ReProgram.🔑 KEYWORDSPartial Reprogramming • ER-100 • OSK • Epigenetics • Glaucoma • Cell Identity • Aging Clocks • Healthspan📌 KEY TAKEAWAYS• Partial reprogramming aims to change cellular state while preserving specialized function.• Early observations in three participants justify further study, not a conclusion of human age reversal.• Improvement at visual-field test locations is not a percentage gain in overall vision.• Control of gene expression does not establish that every downstream effect is reversible.• Durable patient benefit, controlled comparisons, and replication matter more than a younger-looking test alone.🎙️ THE REPROGRAM PERSPECTIVEA treatment can be a major medical advance without proving that aging has been reversed.The goal is useful function, resilience, and more time living well. Hope and demanding scientific questions belong together.⏱️ CHAPTERS00:00 Can we reverse aging—and what would count?01:30 The ReProgram opening01:38 Partial reprogramming and the evidence cutoff02:18 Cell identity and the epigenome03:22 Yamanaka factors and pluripotency04:23 The challenge of partial reprogramming05:16 What mouse studies establish06:01 Beyond a universal reset button06:51 Vision, OSK, and preclinical evidence08:42 ER-100 and early human observations10:30 Understanding the visual-field measurement11:49 What a small early trial can tell us12:50 Variability, learning, and alternative explanations15:39 Cell identity and safety16:16 Delivery, control, and reversibility17:32 Company announcements and complete evidence18:05 Clinical benefit versus tissue rejuvenation19:56 Broader healthspan claims20:35 Aging clocks and meaningful outcomes22:27 What would strengthen the evidence?24:26 Hope, rigor, and the next experiments25:23 Closing thoughts and subscribe📝 NOTES AND REFERENCES1. Takahashi & Yamanaka. Induction of pluripotent stem cells (Cell, 2006).https://doi.org/10.1016/j.cell.2006.07.0242. Ocampo et al. In vivo partial reprogramming (Cell, 2016).https://doi.org/10.1016/j.cell.2016.11.0523. Lu et al. Reprogramming to recover youthful epigenetic information and restore vision (Nature, 2020).https://doi.org/10.1038/s41586-020-2975-44. Life Biosciences. Interim company announcement, October 8, 2026; preliminary findings, not a full trial publication.https://www.lifebiosciences.com/life-biosciences-announces-first-in-human-data-from-ongoing-phase-1-trial-evaluating-er-100-in-optic-neuropathies/5. ER-100 trial registration, NCT07290244.https://clinicaltrials.gov/study/NCT07290244💬 JOIN THE CONVERSATIONWhat evidence would convince YOU that a treatment meaningfully rejuvenated human tissue—and what should the next study measure?Subscribe to The ReProgram for longevity biology without the hype.https://www.youtube.com/@ReProgramPodcastMechanism over marketing. Evidence over anecdotes. Trade-offs over hype.

🎬 EPISODE OVERVIEWCan you actually eat like a centenarian to extend your life? We examine the evidence behind dietary habits and aging.Dr. Paola Sebastiani joins us to discuss the complexities of longevity science and why the current diet of someone who has lived to 100 may not reflect the factors that helped them reach that age. We unpack how metabolomics provides clues about physiological decline, while emphasizing that a single blood marker does not establish cause and effect for long-term health.Our conversation addresses common myths regarding protein intake and the role of genetics in exceptional longevity. By analyzing the data from the New England Centenarian Study, we separate biological mechanisms from marketing claims to understand what truly supports healthy aging. We also look at the limitations of biological age tests and why standardization remains a critical challenge in current research.If you value longevity science without the hype, subscribe to The ReProgram for weekly evidence-based breakdowns. What is one belief about food and aging you would be willing to reconsider?👤 ABOUT THE SPEAKERDr. Paola Sebastiani is a Professor at Tufts University School of Medicine and Director of the Tufts CTSI Biostatistics, Epidemiology, and Research Design Center. A biostatistician studying genetics and exceptional longevity, she and her group lead data analyses for the New England Centenarian Study.Official profile: https://disc.tufts.edu/paola-sebastiani🔑 KEYWORDSPaola Sebastiani • Centenarians • Nutrition • Metabolomics • Protein • Healthy Aging • Longevity Genetics • Biological Age📌 KEY TAKEAWAYS• Metabolites offer clues about aging, but a blood marker does not by itself establish cause and effect.• A centenarian’s current diet may differ from the diet they followed decades earlier. Longitudinal studies matter.• Protein findings from animal studies do not automatically translate to older adults. Sebastiani also cautions against assuming more is always better.• Centenarians are a diverse group; no single food or genetic explanation captures every path to exceptional longevity.• Sebastiani emphasizes standardization and interpretation when discussing biological-age tests.🎙️ THE REPROGRAM PERSPECTIVEA longevity headline can turn an association into an apparent prescription. We need to ask who was studied, what was measured, and whether a finding predicts better health or simply accompanies it.The goal is to preserve health, function, and independence—not just chase a number.⏱️ CHAPTERS00:00 Should we eat like a centenarian?00:58 Introducing Paola Sebastiani01:57 An unexpected route into longevity research03:56 The Cell Reports paper and metabolomics06:04 Nutrition and the dark-chocolate connection07:19 Why following people over time matters09:01 Essential amino acids and dietary changes14:12 What do centenarians eat?18:31 Protein restriction versus aging well20:39 Protein sources and pumpkin seeds22:40 Dietary fats23:26 Genes, nutrition, and longevity families26:57 Centenarian misconceptions27:43 Biological-age tests28:57 Healthspan and longevity interventions30:05 The unresolved genetics of longevity31:08 Activity tracking and personal habits33:21 What aging well means34:20 Closing thoughts📝 NOTES AND REFERENCES1. Sebastiani P et al. Metabolite signatures of chronological age, aging, survival, and longevity. Cell Reports (2024);43(11):114913.https://doi.org/10.1016/j.celrep.2024.114913Open-access paper: https://pmc.ncbi.nlm.nih.gov/articles/PMC11656345/💬 JOIN THE CONVERSATIONWhat is one belief about food and aging you would be willing to reconsider?Subscribe to The ReProgram for more conversations about livingwell.https://www.youtube.com/@ReProgramPodcastLongevity Biology Without the HypeMechanism over marketing. Evidence over anecdotes. Trade-offs over hype.

🎬 EPISODE OVERVIEWDoes your fish oil capsule deserve its reputation? In Episode 31, I review omega-3s for heart health, cognition, and healthy aging, then give five evidence scores and an overall C+.We examine VITAL, REDUCE-IT, STRENGTH, newer DHA research, aging clocks, and safety. Eating fish, taking supplements, and using prescription omega-3s are different questions.🔑 KEYWORDSOmega-3 • Fish Oil • EPA • DHA • Triglycerides • Cognition • Aging Clocks • Atrial Fibrillation • Longevity📌 KEY TAKEAWAYS• Triglyceride lowering: 5/5 at studied therapeutic doses.• Routine cardiovascular prevention in generally healthy adults: 2/5. Prescription EPA in selected high-risk patients is a separate clinical decision.• Preventing cognitive decline in generally healthy older adults: 1/5.• Epigenetic aging clocks: 2/5. Small changes in clock estimates do not establish longer life.• Extending human lifespan through routine supplementation: 1/5.• Overall: C+ for routine OTC fish oil as a healthy-aging intervention; this is my assessment, not a mathematical average. Dose, formulation, and baseline risk matter.🎙️ THE REPROGRAM PERSPECTIVEA biological mechanism or improved test result is a starting point. Ask whether the evidence shows better health, function, or survival in people like you. Educational discussion; understand prescribed treatment with your clinician before making changes.⏱️ CHAPTERS00:00 What has fish oil earned?00:55 The Scorecard framework01:16 Fish, supplements, and prescription products01:56 Read the EPA and DHA label02:27 Triglycerides: the strongest evidence03:43 VITAL and heart prevention04:39 REDUCE-IT and prescription EPA05:50 STRENGTH and conflicting results07:08 Brain health and the DHA trials08:34 DO-HEALTH and aging clocks09:59 Heart-rhythm risk and interactions11:37 Five claims, five scores13:22 The C+ verdict and its limits14:27 Questions to ask about your supplement15:31 Closing perspective💬 JOIN THE CONVERSATIONIf you take fish oil, what benefit are you hoping for—and does the evidence match that goal?Subscribe to The ReProgram: https://www.youtube.com/@ReProgramPodcastLongevity Biology Without the Hype.Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.

🎬 EPISODE OVERVIEWCan a younger clock score translate into better health?In Episode 30, I sit down with Dr. Steve Horvath to explore epigenetic clocks, biological-age claims, and his vision for rejuvenation.We discuss why there are so many clocks, what stands between research and patient care, prevention, and why progress may come one organ at a time.👤 ABOUT THE SPEAKERDr. Steve Horvath is Professor of Medicine and Director of Aging Biology Research at UCLA’s David Geffen School of Medicine. A geroscientist and biostatistician, he developed the influential 2013 multi-tissue DNA methylation clock.Lab profile: https://horvathaginglab.org/🔑 KEYWORDSSteve Horvath • Epigenetic Clocks • DNA Methylation • Biological Age • Rejuvenation • Prevention • Aging Biomarkers • Geroscience📌 KEY TAKEAWAYS• Different aging clocks can produce different results. Horvath argues for transparent reporting across multiple clocks.• Dramatic age-reversal claims deserve scrutiny; a younger test result needs meaningful interpretation.• Horvath sees promise in clinical use, while emphasizing that routine patient care is not there yet.• Rejuvenation is connected to prevention: the aim is to preserve health before disease develops.• A realistic path may focus on individual organs rather than a single treatment for the entire body.🎙️ THE REPROGRAM PERSPECTIVEBetter measurement can sharpen the questions we ask about aging. The next challenge is connecting those measurements to outcomes that matter to people.Our focus: what changed, how reliably was it measured, and what does it mean for health and function?⏱️ CHAPTERS00:00 Can we measure and reverse aging?00:51 Introducing Steve Horvath01:40 Reinventing a research career05:28 Why are there so many aging clocks?07:51 Bringing clocks into clinical practice09:16 Evaluating age-reversal claims11:31 Rejuvenation and prevention14:37 What does rejuvenation mean?16:26 One organ at a time18:36 Lifestyle, testing, and perspective20:57 Closing thoughts📝 NOTES AND REFERENCESRelated papers featured in the edit:1. Horvath S. DNA methylation age of human tissues and cell types. Genome Biology (2013).https://doi.org/10.1186/gb-2013-14-10-r1152. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nature Reviews Genetics (2018).https://doi.org/10.1038/s41576-018-0004-33. Lu Y et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature (2020).https://doi.org/10.1038/s41586-020-2975-4The Lu study is preclinical mouse research, not evidence of whole-body age reversal in humans.💬 JOIN THE CONVERSATIONWhat would convince you that an intervention truly rejuvenates: a younger clock score, better organ function, or both?Subscribe to The ReProgram for longevity biology without the hype.https://www.youtube.com/@ReProgramPodcastMechanism over marketing. Evidence over anecdotes. Trade-offs over hype.